Tag
The post discusses the potential of bioelectricity in future medicine, highlighting Dr. Michael Levin's research on reprogramming cells through electrical signals and suggesting that next-generation pharmaceutical companies will focus on this field.
First person treated in a gene therapy trial using partial reprogramming to rejuvenate cells, aiming to treat glaucoma by regenerating optic nerve neurons.
New Limit's cellular reprogramming therapy, delivered via mRNA in lipid nanoparticles, restores liver resilience and improves survival in aged mice subjected to repeated alcohol cycles, with human trials planned next year in Australia.